Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine dispersible tablets for uncomplicated malaria in infants under 5 kg
PACTR201302000476155Completed
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Open-label, single-arm trial of artemether + lumefantrine in malaria and Falciparum malaria (PF), sponsored by Novartis. Primary endpoint: PCR-corrected 28-day parasitological cure rate. Started Oct 2012; status: completed.
02
Drugs
artemether + lumefantrine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on PACTR201302000476155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201302000476155.